-
AbbVie Q3 2024 Financial statements
Financial statements
In Q3 2024, AbbVie reported net revenues of $14.460 billion, a 3.8% year-on-year increase. Skyrizi surged by 50.8% to $3.205 billion, offsetting Humira's decline due to generics. Diverse segments, including Oncology and Neuroscience, showed solid growth, while strategic acquisitions.
文昌市|
古浪县|
和平县|
安徽省|
富阳市|
洛扎县|
济阳县|
隆德县|
济南市|
定西市|
江山市|
崇州市|
浑源县|
湖口县|
榆中县|
慈溪市|
全州县|
凤山市|
微山县|
澄江县|
屏边|
分宜县|
定安县|
囊谦县|
阿拉善盟|
剑川县|
迁西县|
长海县|
长泰县|
阳春市|
涪陵区|
泸水县|
萨嘎县|
长阳|
体育|
阿鲁科尔沁旗|
景宁|
拜城县|
邯郸市|
肥乡县|
高阳县|